Aquestive Therapeutics (AQST) announced the appointment of Thomas Zalewski as chief legal officer and chief compliance officer, effective April 2, succeeding Lori Braender, who will be stepping down as chief legal officer and chief compliance officer and remaining as corporate secretary of the company. Zalewski joins Aquestive as chief legal officer and chief compliance officer effective April 2. Zalewski is a partner at Day Pitney, where he serves as chair of the firm’s healthcare and life sciences practice.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics Faces Investor Lawsuit Over Alleged FDA Approval Misrepresentations for Anaphylm
- Reiterating Buy on Aquestive: Near-Term Cost Pressures Offset by Anaphylm-Driven 2027 Growth Potential and $10 Target
- Aquestive Therapeutics Maps Risky Path to ANNAFILM Launch
- AI Execution Risks Threaten Aquestive Therapeutics’ Competitiveness and Profitability
- Aquestive Therapeutics price target lowered to $9 from $12 at Alliance Global